WallStSmart

Artivion Inc (AORT)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 1274% more annual revenue ($6.30B vs $458.69M). EW leads profitability with a 17.4% profit margin vs 2.5%. EW appears more attractively valued with a PEG of 2.05. EW earns a higher WallStSmart Score of 61/100 (C+).

AORT

Hold

41

out of 100

Grade: D

Growth: 6.7Profit: 4.5Value: 2.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.46

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AORTSignificantly Overvalued (-31.9%)

Margin of Safety

-31.9%

Fair Value

$30.41

Current Price

$20.12

$10.29 premium

UndervaluedFair: $30.41Overvalued
EWUndervalued (+68.6%)

Margin of Safety

+68.6%

Fair Value

$252.36

Current Price

$85.96

$166.40 discount

UndervaluedFair: $252.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AORT2 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
17.5%8/10

17.5% revenue growth

EW4 strengths · Avg: 9.5/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

AORT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$971.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.6%3/10

ROE of 2.6% — below average capital efficiency

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.054/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : AORT

The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : AORT

The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 80.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Key Dynamics to Monitor

AORT carries more volatility with a beta of 1.26 — expect wider price swings.

AORT is growing revenue faster at 17.5% — sustainability is the question.

AORT generates stronger free cash flow (-7M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EW scores higher overall (61/100 vs 41/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Artivion Inc

HEALTHCARE · MEDICAL DEVICES · USA

Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?